The treatment of Parkinson's disease with levodopa has been discussed...
Published Thursday 04 December 2008
Annual report finds cancer initiative a success
A new initiative that aims to improve the treatment of...
Published Thursday 04 December 2008
New game could help tackle obesity and diabetes in kids, expert claims
A new scheme from the British Heart Foundation (BHF) will...
Published Thursday 04 December 2008
Some "good cholesterol" not good enough, study suggests
A number of preconceptions about "good" HDL cholesterol have been...
Published Tuesday 02 December 2008
More Medical News
Men’s Health - Andrology
Please note - this EPG Men's health Knowledge Centre is for Doctors and other Health Care Professionals.
Male hypogonadism is the term used to describe decreased functional activity of the testes with diminished production and action of testosterone. Three different categories of hypogonadism are distinguished depending on the organs or organ systems responsible for the disturbance. These are:
- Primary hypogonadism (hypergonadotropic hypogonadism)
- Secondary hypogonadism (hypogonadotropic hypogonadism)
- Target organ resistance (androgen resistance)
The clinical picture of hypogonadism depends on whether the androgen deficiency occurs during the fetal period, before puberty or in adulthood.
Hypogonadism can be caused by a number of disorders, the most frequently observed being idiopathic hypogonadotrophic hypogonadism, hypopituitarism, Klinefelter’s syndrome or late-onset hypogonadism.
Hypogonadism is a clinical condition characterized by low serum testosterone levels occurring in association with a number of the signs and symptoms. If symptoms of testosterone deficiency are present, the doctor will investigate them using various diagnostic procedures.
In all forms of male hypogonadism, androgen therapy forms the core of the treatment. If there is a desire for fertility it may be necessary to temporarily interrupt the treatment and use other procedures instead.
Enter the Men's Health Knowledge Centre
What’s in this Men's Health Knowledge Centre?
Home | Hypogonadism | Epidemiology | Etiology | Physiology and Pathophysiology | Biologic Effects of Androgens | Rationale for Therapy | Late-onset Hypogonadism (LOH) | Symptoms | Diagnosis of hypogonadism | Therapy Options | Initiating Treatment | Monitoring | Safety and Tolerability | Clinical Trials/Studies | Reviews | Algorithm | Patient Questionanaire and Evaluation Sheet

Medical News


![The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC] The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]](/images/banners/nsclc.gif)
